Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug

• D. Perlstein ,

  Contributed equally to this work with: D. Perlstein, O. Shlagman

  Roles Formal analysis, Methodology, Software, Writing – review & editing

  Affiliation Institute for Medical Biomathematics (IMBM), Bene Ataroth, Israel

  ⨯
• O. Shlagman ,

  Contributed equally to this work with: D. Perlstein, O. Shlagman

  Roles Conceptualization, Methodology

  Affiliation Institute for Medical Biomathematics (IMBM), Bene Ataroth, Israel

  ⨯
• Y. Kogan,

  Roles Methodology, Supervision, Writing – review & editing

  Affiliation Institute for Medical Biomathematics (IMBM), Bene Ataroth, Israel

  ⨯
• K. Halevi-Tobias,

  Roles Investigation, Methodology

  Affiliation Institute for Medical Biomathematics (IMBM), Bene Ataroth, Israel

  ⨯
• A. Yakobson,

  Roles Data curation, Resources

  Affiliation Department of Oncology, Soroka University Medical Center, Be'er Sheba, Israel

  ⨯
• I. Lazarev,

  Roles Data curation, Resources, Writing – review & editing

  Affiliation Department of Oncology, Soroka University Medical Center, Be'er Sheba, Israel

  ⨯
• Z. Agur

  Roles Conceptualization, Methodology, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: agur@imbm.org

  Affiliation Institute for Medical Biomathematics (IMBM), Bene Ataroth, Israel

  http://orcid.org/0000-0001-5701-9149

  ⨯